文献速递胸部肿瘤放疗

不可切除IIIA/IIIB期非小细胞肺癌同步放化疗后巩固免疫治疗(纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药)的2期研究中放射性肺炎评估

Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-10-26

本研究基于BTCRC-LUN16-081随机2期试验,评估不可切除IIIA/IIIB期非小细胞肺癌患者同步放化疗后接受纳武利尤单抗或纳武利尤单抗联合伊匹木单抗巩固治疗时放射性肺炎的风险。104例可评估患者中29例(27.9%)发生≥2级肺炎,肺V20>23%与≥2级肺炎风险升高相关(37.1% vs 16.2%,P=0.031),两治疗组间肺炎发生率无显著差异,传统肺剂量体积参数(V5>65%、V20>35%、平均剂量>20 Gy)与肺炎无关。

要点

  • 肺V20>23%患者≥2级肺炎发生率显著高于V20≤23%者(37.1% vs 16.2%,P=0.031)。
  • 纳武利尤单抗单药组与联合伊匹木单抗组肺炎发生率无显著差异。
  • 传统肺剂量体积参数(V5>65%、V20>35%、平均剂量>20 Gy)与肺炎无关联。

核心结论

  • 在接受根治性同步放化疗后纳武利尤单抗或纳武利尤单抗联合伊匹木单抗巩固治疗的患者中,肺V20>23%与≥2级放射性肺炎风险升高相关。
  • 同步放化疗后接受巩固免疫治疗患者的肺剂量约束应继续评估并在可行时优化。

研究设计与样本

  • BTCRC-LUN16-081是一项随机2期试验,评估同步放化疗后巩固纳武利尤单抗对比纳武利尤单抗联合伊匹木单抗治疗6个月的疗效与耐受性。
  • 共入组105例不可切除IIIA/IIIB期非小细胞肺癌患者,54例接受纳武利尤单抗单药,51例接受纳武利尤单抗联合伊匹木单抗;其中104例有剂量体积直方图信息。
  • 104例中65例(62.5%)为IIIA期,39例(37.5%)为IIIB期(美国癌症联合委员会第7版分期)。

主要发现

  • 研究期间29例(27.9%)诊断为≥2级肺炎。
  • 采用逻辑回归评估肺V20不同截断值,V20>23%患者≥2级肺炎发生率显著更高(37.1% vs 16.2%,P=0.031)。
  • 两治疗组间肺炎发生率无显著差异。
  • 传统肺剂量体积直方图截断值(V5>65%、V20>35%、平均剂量>20 Gy)与肺炎无关联。

临床怎么用

  • 原文结论指出,同步放化疗后接受巩固免疫治疗患者的肺剂量约束应继续评估并在可行时优化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The addition of immunotherapy (IO) after concurrent chemoradiation therapy (CCRT) for unresectable non-small cell lung cancer (NSCLC) has become common practice in eligible patients. Approaches to further improve outcomes and reduce treatment-related toxicity for these patients are needed. This study evaluates the risk of radiation pneumonitis after CCRT and its correlation with the radiation dose distribution, IO regimen (nivolumab vs nivolumab plus ipilimumab), and patient demographics across BTCRC-LUN16-081. METHODS AND MATERIALS: Patients with unresectable stage III NSCLC after completion of CCRT were enrolled in BTCRC-LUN16-081, a randomized phase 2 trial to assess the efficacy and tolerability of consolidative nivolumab versus nivolumab plus ipilimumab for 6 months. Radiation dose parameters, patient demographics, and toxicity events were evaluated among treatment arms for risk and severity of pneumonitis. RESULTS: One hundred-five patients were enrolled into 2 treatment arms; 54 patients received nivolumab alone, and 51 patients received nivolumab plus ipilimumab. Of these, 104 patients had dose-volume histogram information available. Within this cohort, 65 patients (62.5%) had stage IIIA, and 39 patients (37.5%) had stage IIIB NSCLC disease, per the American Journal Committee on Cancer, seventh edition. During the study, 29 patients (27.9%) were diagnosed with grade 2 or greater pneumonitis. Using logistic regression and evaluating different cutoffs for percentage of normal lung volume receiving at least 20 gy (V20), patients with V20 > 23% demonstrated significantly higher grade 2 or greater pneumonitis rates (37.1% vs 16.2%, P = .031). No significant difference in rates of pneumonitis between arms was identified. Traditional lung dose-volume histogram cutoffs (percentage of normal lung volume receiving at least 5 gy (V5) > 65%, V20 > 35%, and mean > 20 Gy) were not associated with pneumonitis. CONCLUSIONS: In patients receiving nivolumab or nivolumab plus ipilimumab after definitive CCRT, lung V20 > 23% was associated with an increased risk of grade 2 or greater pneumonitis. Radiation dose constraints for lungs in patients receiving consolidative IO after CCRT should continue to be evaluated and optimized when feasible.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Weisman M, Durm G, Shields MD, et al. Evaluation of Radiation Pneumonitis in a Phase 2 Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation Therapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39490906. doi:10.1016/j.ijrobp.2024.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。